Screener
Aclaris Therapeutics ACRS Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other current liabilities | 2,790 | 2,753 |
| Total current liabilities | 28,241 | 28,645 |
| Other liabilities | 1,262 | 1,565 |
| Deferred income, net of current portion | 14,309 | 16,168 |
| Contingent consideration | 11,300 | 11,000 |
| Total liabilities | 55,112 | 57,378 |
| Stockholders’ Equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at June 30, 2026 and December 31, 2025 | — | — |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's contract liabilities?
- Aclaris Therapeutics (ACRS) reported contract liabilities of $14.31M in Q2 2026.
- How has Aclaris Therapeutics's contract liabilities changed year-over-year?
- Aclaris Therapeutics's contract liabilities decreased by 21.5% year-over-year, from $18.22M to $14.31M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Aclaris Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude